{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.5","upperLimit":"22.5","value":"14.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"110"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants in the analysis population who experienced a CR (disappearance of all target lesions) or a PR (at least a 30% decrease in the sum of diameters of target lesions) and was assessed using RECIST 1.1 based on BICR evaluation. The percentage of participants who were previously treated with cetuximab and platinum and experienced a CR or PR in the Cohorts B and B2 was presented for the first course of pembrolizumab treatment per protocol.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received pembrolizumab, 10 mg/kg, IV once every 2 weeks (Cohort B) or pembrolizumab, 200 mg, IV once every 3 weeks (Cohort B2), and continued to receive study drug until disease progression, death, withdrawal of consent, Investigator decision, or end of study (up to 2 years). Participants who stopped study treatment without progression (e.g. completed 2 years) may have been eligible for up to 1 year of retreatment upon subsequently experiencing disease progression.","id":"OG000","title":"Cohorts B & B2: Head & Neck Cancer"}],"paramType":"NUMBER","populationDescription":"The population consisted of all Cohort B or B2 participants who progressed following cetuximab and platinum therapy and received ≥1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Every 8 weeks until disease progression (Up to ~ 35 months) - through FA cutoff date 26 Apr 2016","title":"Overall RECIST 1.1 Response Rate Based on BICR Review, for Participants Previously Treated With Cetuximab and Platinum in Cohorts B and B2","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}